Relief Therapeutics Holding AG - Asset Resilience Ratio
Relief Therapeutics Holding AG (RLF) has an Asset Resilience Ratio of 0.01% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RLF current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2023)
This chart shows how Relief Therapeutics Holding AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Relief Therapeutics Holding AG total assets.
Liquid Assets Composition Over Time
This chart breaks down Relief Therapeutics Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Relief Therapeutics Holding AG for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF9.00K | 0.01% |
| Total Liquid Assets | CHF9.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Relief Therapeutics Holding AG maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Relief Therapeutics Holding AG Industry Peers by Asset Resilience Ratio
Compare Relief Therapeutics Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Relief Therapeutics Holding AG (2006–2023)
The table below shows the annual Asset Resilience Ratio data for Relief Therapeutics Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.01% | CHF9.00K ≈ $11.38K |
CHF76.39 Million ≈ $96.58 Million |
0.00pp |
| 2022-12-31 | 0.01% | CHF28.00K ≈ $35.40K |
CHF188.80 Million ≈ $238.69 Million |
-- |
| 2021-12-31 | 0.00% | CHF0.00 ≈ $0.00 |
CHF251.62 Million ≈ $318.11 Million |
-- |
| 2020-12-31 | 0.24% | CHF185.00K ≈ $233.89K |
CHF78.05 Million ≈ $98.67 Million |
+0.18pp |
| 2013-12-31 | 0.06% | CHF25.73K ≈ $32.54K |
CHF45.98 Million ≈ $58.13 Million |
-18.38pp |
| 2006-12-31 | 18.43% | CHF14.15 Million ≈ $17.89 Million |
CHF76.76 Million ≈ $97.05 Million |
-- |
About Relief Therapeutics Holding AG
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more